Clinical trial
A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Lead sponsor
- Janssen Research & Development, LLC
- Phase
- Phase 2/3
- Overall status
- Recruiting
- Start date
- October 3, 2025
- Completion date
- October 16, 2032
- Enrollment
- 1,092 (estimated)
- Sites
- 372
Conditions
As the registry lists them; a condition with its own page is linked.